AKT1 and breast cancer: In combination with a PD-1 inhibitor, SHFe@TG synergistically inhibits the Phosphoinositide 3-Kinase–Protein Kinase B (PI3K–AKT) signaling pathway, thereby suppressing BC cell proliferation (Zhao et al., 2025).